Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dyne Therapeutics Inc. (DYN:NASDAQ), powered by AI.
Dyne Therapeutics Inc. is currently trading at $18.07. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dyne Therapeutics Inc. on Alpha Lenz.
View Dyne Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Dyne Therapeutics Inc.'s ROE is -55.7%. Explore profitability and growth together.”
Ask for details →Dyne Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with genetically-driven muscle diseases. The organization is committed to addressing unmet medical needs by enhancing muscle function and improving the quality of life for individuals suffering from disorders such as muscular dystrophies. Dyne Therapeutics employs cutting-edge technology and specialists to design precision medicine modalities, aiming for significant advancements in the field of muscle biology and therapeutics. Operating primarily within the biopharmaceutical sector, Dyne's mission is grounded in deploying its proprietary FORCE platform to deliver RNA therapies precisely to affected tissues, thereby amplifying therapeutic efficacy while minimizing off-target risks. The company's strategic research endeavors are instrumental in driving potential breakthroughs especially in disorders where current treatment options are limited or non-existent. In the broader financial market, Dyne Therapeutics Inc. contributes to the overall growth and innovation within the healthcare and biotechnology sectors. By focusing on niche areas with high demand for specialized treatments, Dyne plays a critical role in progressing the development pipeline for novel drugs, aligning with the broader goals of advancing health solutions and expanding therapeutic possibilities.
“Dyne Therapeutics Inc.'s ROE is -55.7%. Explore profitability and growth together.”
Ask for details →Dyne Therapeutics Inc. (ticker: DYN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 206 employees.
The current price is $18.07 with a P/E ratio of -x and P/B of -x.
ROE is -55.71%.